药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Lampalizumab
The risk or severity of adverse effects can be increased when Lampalizumab is combined with Polatuzumab vedotin.
Difenoxin
Sirukumab
The risk or severity of adverse effects can be increased when Sirukumab is combined with Polatuzumab vedotin.
Difenoxin
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Polatuzumab vedotin.
Difenoxin
Tremelimumab
The risk or severity of adverse effects can be increased when Tremelimumab is combined with Polatuzumab vedotin.
Difenoxin
Solanezumab
The risk or severity of adverse effects can be increased when Solanezumab is combined with Polatuzumab vedotin.
Difenoxin
Onartuzumab
The risk or severity of adverse effects can be increased when Onartuzumab is combined with Polatuzumab vedotin.
Difenoxin
Depatuxizumab mafodotin
The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Polatuzumab vedotin.
Difenoxin
Bapineuzumab
The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Polatuzumab vedotin.
Difenoxin
Durvalumab
The risk or severity of adverse effects can be increased when Durvalumab is combined with Polatuzumab vedotin.
Difenoxin
Figitumumab
The risk or severity of adverse effects can be increased when Figitumumab is combined with Polatuzumab vedotin.
Difenoxin
Ficlatuzumab
The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Polatuzumab vedotin.
Difenoxin
Tabalumab
The risk or severity of adverse effects can be increased when Tabalumab is combined with Polatuzumab vedotin.
Difenoxin
Conatumumab
The risk or severity of adverse effects can be increased when Conatumumab is combined with Polatuzumab vedotin.
Difenoxin
Human Varicella-Zoster Immune Globulin
The risk or severity of adverse effects can be increased when Human Varicella-Zoster Immune Globulin is combined with Polatuzumab vedotin.
Difenoxin
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Polatuzumab vedotin.
Difenoxin
Tetanus Immune Globulin
The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Polatuzumab vedotin.
Difenoxin
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Polatuzumab vedotin.
Difenoxin
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Polatuzumab vedotin.
Difenoxin
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Polatuzumab vedotin.
Difenoxin
Necitumumab
The risk or severity of adverse effects can be increased when Necitumumab is combined with Polatuzumab vedotin.